血清标志物（NSE、CEA、CA-125、CYFRA21-1）和分子标志物（MDR-1、LRP、RRM-1、EGFR、ERCC-1、BRCA-1）在非小细胞肺癌患者原发灶和转移淋巴结的表达  

Expression of serum markers （ NSE, CEA, CA-125, CYFRA 21-1 ） and molecular markers （MDR-1, LRP, RRM-1, EGFR, ERCC- 1, BRCA-1 ） in primary sites and metastatic lymph nodes of lung cancer patients

作　　者：郭楠楠[1] 李珊珊[2] 张文[1] 于长海[1] 俞建琦[1] 李少军[1] 

机构地区：[1]解放军总医院第一附属医院胸心外科,北京100048 [2]解放军第309医院西山门诊部,北京100091

出　　处：《转化医学电子杂志》2014年第1期24-29,共6页E-Journal of Translational Medicine

摘　　要：目的：研究不同血清标志物及分子标志物在肺癌不同病理亚型、原发灶与转移淋巴结间表达的差异．方法：对48例住院接受开胸手术切除原发病灶及转移淋巴结的患者进行4种血清标志物和6种分子标记物检测．结果：ERCC-1的表达在原发肿瘤和转移部位间有显著差异（P=0．007）；CEA的血清水平在不同肿瘤亚型患者间存在显著差异（P=0．008）．结论：标志物检测对于患者预后的判断及治疗方案具有一定价值．AIM： To investigate the different expressions of ser um markers and molecular markers in the primary tumor and the metastatic lymph nodes of lung cancer patients with four histologi cal subtypes. METHODS： There were 48 cases of lung cancer patients who underwent thoracic surgery for removal of primary and metastatic lesions had been enrolled for testing. RESULTS： Expression of ERCC-1 was significantly different in primary tumors and metastatic sites （ P = 0. 007） and the serum level of CEA was significantly different for patients with different cancer subtypes （P = 0. 008 ）. CONCLUSION： Tumor molecular markers have value to estimate prognosis and select treatments for patients.

关 键 词：非小细胞肺癌 转移淋巴结 分子标志物 血清标志物 

分 类 号：R734[医药卫生—肿瘤]